Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun:74:49-53.
doi: 10.1016/j.curtheres.2013.02.003.

Fondaparınux versus nadroparın for preventıon of venous thromboembolısm after electıve hıp and knee arthroplasty

Mahmut Argun  1 , Mithat Oner  1 , Mehmet Saglamoglu  1 , Ibrahim Karaman  1 , Ahmet Guney  1 , Mehmet Halici  1 , Ibrahim Halil Kafadar  1
Affiliations

Fondaparınux versus nadroparın for preventıon of venous thromboembolısm after electıve hıp and knee arthroplasty

Mahmut Argun et al. Curr Ther Res Clin Exp. 2013 Jun.

Abstract

Objective: To evaluate the efficacy and safety of fondaparinux compared with nadroparin for prevention of venous thromboembolism after arthroplasty.

Patients and methods: One hundred fifteen patients were randomized into 2 treatment groups. Patients were given fondaparinux in Group I and nadroparin in Group II. Measurements were performed on Days 1, 5, and 21. The wound area was assessed with a subjective visual analog scale.

Results: The blood counts, clinical biochemical tests, and coagulation tests (ie, thrombin time, partial thromboplastin time, activated partial thromboplastin time, fibrinogen, prothrombin time-International Normalized Ratio, and antithrombin III activity) did not show statistically significant differences between Group I and Group II. In both study groups, anti-factor Xa activities increased significantly on the fifth and 21st day. The scores of the subjective visual analog scale showed significance on Day 21.

Conclusions: Our results confirm the safety and efficacy of both fondaparinux and nadroparin for prophylaxis after major orthopedic surgery.

Keywords: arthroplasty; fondaparinux; nadroparin; venous thromboembolism.

PubMed Disclaimer

References

    1. Frostick S.P. Death after joint replacement. Haemostasis. 2000;30:84–87. - PubMed
    1. White R.H., Romano P.S., Zhou H. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158:1525–1531. - PubMed
    1. Nicolaides A.N. Prevention of venous thromboembolism: international consensus statement, guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001;20:1–37. - PubMed
    1. McMillan W.D., McCarthy W.J., Lin S.J. Perioperative low molecular weight heparin for infrageniculate bypass. J Vasc Surg. 1997;25:796–802. - PubMed
    1. Turpie A.G., Gallus A.S., Hoek J.A. Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619–625. - PubMed

LinkOut - more resources